文献速递乳腺癌

四种乳腺癌风险预测模型的10年性能:一项验证研究

10-year performance of four models of breast cancer risk: a validation study.
PubMed 文献 · Lancet Oncol · 2019-02-21

该验证研究利用乳腺癌前瞻性家族研究队列(ProF-SC)中来自澳大利亚、加拿大和美国的18 856名女性,在1992年3月17日至2011年6月29日期间招募时无乳腺癌,最终选取15 732名女性计算10年风险评分,比较BOADICEA、BRCAPRO、BCRAT和IBIS四种模型的校准度和区分度。中位随访11.1年后,619名(4%)女性被前瞻性诊断为乳腺癌。BOADICEA和IBIS在整体验证队列中校准良好,而BRCAPRO和BCRAT低估风险;BOADICEA和IBIS的C统计量分别为0.70和0.71。

要点

  • BOADICEA和IBIS在整体队列中校准良好,BRCAPRO和BCRAT低估风险。
  • 整体队列C统计量:BOADICEA 0.70,IBIS 0.71,BRCAPRO 0.68,BCRAT 0.60。
  • BOADICEA和IBIS的预测评分受限于仅输入一、二级亲属家族史的影响不大。

核心结论

  • 包含多代家族史的模型如BOADICEA和IBIS具有更好的乳腺癌风险预测能力,即使对平均或低于平均风险的女性也是如此。
  • BOADICEA和IBIS表现相似,但结合BOADICEA的多基因风险成分和IBIS的非家族史风险因素的混合模型可能进一步提高预测准确性。

研究设计与样本

  • 验证研究,使用乳腺癌前瞻性家族研究队列(ProF-SC),该队列包括来自澳大利亚、加拿大和美国的18 856名招募时无乳腺癌的女性,招募时间为1992年3月17日至2011年6月29日。
  • 选取20-70岁、无双侧预防性乳房切除或卵巢癌史、至少2个月随访数据且有乳腺癌家族史信息的女性,最终15 732名女性纳入分析。
  • 计算10年风险评分,比较BOADICEA、BRCAPRO、BCRAT和IBIS四种模型,基于期望病例数与观察病例数比值评估校准度,基于C统计量评估区分度。
  • 进行亚组分析:BRCA1或BRCA2突变携带者(BRCA阳性)、非携带者和未检测参与者(BRCA阴性)、招募时年龄小于50岁的参与者;并评估限制数据输入对模型性能的影响。

主要发现

  • 中位随访11.1年(IQR 6.0-14.4),15 732名女性中619名(4%)被前瞻性诊断为乳腺癌,其中519名(84%)为组织学确诊。
  • 整体验证队列中,期望病例数与观察病例数比值:BOADICEA 1.05(95% CI 0.97-1.14),IBIS 1.03(0.96-1.12),BRCAPRO 0.59(0.55-0.64),BCRAT 0.79(0.73-0.85)。
  • 整体验证队列C统计量:BOADICEA 0.70(95% CI 0.68-0.72),IBIS 0.71(0.69-0.73),BRCAPRO 0.68(0.65-0.70),BCRAT 0.60(0.58-0.62)。
  • BRCA阴性女性亚组期望与观察病例数比值:BOADICEA 1.02(95% CI 0.93-1.12),IBIS 1.00(0.92-1.10),BRCAPRO 0.53(0.49-0.58),BCRAT 0.97(0.89-1.06)。
  • BRCA阳性参与者亚组期望与观察病例数比值:BOADICEA 1.17(95% CI 0.99-1.38),IBIS 1.14(0.96-1.35),BRCAPRO 0.80(0.68-0.95)。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Independent validation is essential to justify use of models of breast cancer risk prediction and inform decisions about prevention options and screening. Few independent validations had been done using cohorts for common breast cancer risk prediction models, and those that have been done had small sample sizes and short follow-up periods, and used earlier versions of the prediction tools. We aimed to validate the relative performance of four commonly used models of breast cancer risk and assess the effect of limited data input on each one's performance. METHODS: In this validation study, we used the Breast Cancer Prospective Family Study Cohort (ProF-SC), which includes 18 856 women from Australia, Canada, and the USA who did not have breast cancer at recruitment, between March 17, 1992, and June 29, 2011. We selected women from the cohort who were 20-70 years old and had no previous history of bilateral prophylactic mastectomy or ovarian cancer, at least 2 months of follow-up data, and information available about family history of breast cancer. We used this selected cohort to calculate 10-year risk scores and compare four models of breast cancer risk prediction: the Breast and Ovarian Analysis of Disease Incidence and Carrier Estimation Algorithm model (BOADICEA), BRCAPRO, the Breast Cancer Risk Assessment Tool (BCRAT), and the International Breast Cancer Intervention Study model (IBIS). We compared model calibration based on the ratio of the expected number of breast cancer cases to the observed number of breast cancer cases in the cohort, and on the basis of their discriminatory ability to separate those who will and will not have breast cancer diagnosed within 10 years as measured with the concordance statistic (C-statistic). We did subgroup analyses to compare the performance of the models at 10 years in BRCA1 or BRCA2 mutation carriers (ie, BRCA-positive women), tested non-carriers and untested participants (ie, BRCA-negative women), and participants younger than 50 years at recruitment. We also assessed the effect that limited data input (eg, restriction of the amount of family history and non-genetic information included) had on the models' performance. FINDINGS: After median follow-up of 11·1 years (IQR 6·0-14·4), 619 (4%) of 15 732 women selected from the ProF-SC cohort study were prospectively diagnosed with breast cancer after recruitment, of whom 519 (84%) had histologically confirmed disease. BOADICEA and IBIS were well calibrated in the overall validation cohort, whereas BRCAPRO and BCRAT underpredicted risk (ratio of expected cases to observed cases 1·05 [95% CI 0·97-1·14] for BOADICEA, 1·03 [0·96-1·12] for IBIS, 0·59 [0·55-0·64] for BRCAPRO, and 0·79 [0·73-0·85] for BRCAT). The estimated C-statistics for the complete validation cohort were 0·70 (95% CI 0·68-0·72) for BOADICEA, 0·71 (0·69-0·73) for IBIS, 0·68 (0·65-0·70) for BRCAPRO, and 0·60 (0·58-0·62) for BCRAT. In subgroup analyses by BRCA mutation status, the ratio of expected to observed cases for BRCA-negative women was 1·02 (95% CI 0·93-1·12) for BOADICEA, 1·00 (0·92-1·10) for IBIS, 0·53 (0·49-0·58) for BRCAPRO, and 0·97 (0·89-1·06) for BCRAT. For BRCA-positive participants, BOADICEA and IBIS were well calibrated, but BRCAPRO underpredicted risk (ratio of expected to observed cases 1·17 [95% CI 0·99-1·38] for BOADICEA, 1·14 [0·96-1·35] for IBIS, and 0·80 [0·68-0·95] for BRCAPRO). We noted similar patterns of calibration for women younger than 50 years at recruitment. Finally, BOADICEA and IBIS predictive scores were not appreciably affected by limiting input data to family history for first-degree and second-degree relatives. INTERPRETATION: Our results suggest that models that include multigenerational family history, such as BOADICEA and IBIS, have better ability to predict breast cancer risk, even for women at average or below-average risk of breast cancer. Although BOADICEA and IBIS performed similarly, further improvements in the accuracy of predictions could be possible with hybrid models that incorporate the polygenic risk component of BOADICEA and the non-family-history risk factors included in IBIS. FUNDING: US National Institutes of Health, National Cancer Institute, Breast Cancer Research Foundation, Australian National Health and Medical Research Council, Victorian Health Promotion Foundation, Victorian Breast Cancer Research Consortium, Cancer Australia, National Breast Cancer Foundation, Queensland Cancer Fund, Cancer Councils of New South Wales, Victoria, Tasmania, and South Australia, and Cancer Foundation of Western Australia.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Terry MB, Liao Y, Whittemore AS, et al. 10-year performance of four models of breast cancer risk: a validation study. Lancet Oncol. 2019. PMID: 30799262. doi:10.1016/S1470-2045(18)30902-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。